Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Endometrial02 adjuvant T-DXd vs standard chemotherapy in HER2-expressing endometrial cancer
jRCT2031250423Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in endometrial cancer (EC) comparing Arm A: T-DXd with Arm B: Standard of Care Chemotherapy (2 arms). Primary endpoint: Disease-Free Survival. Started Nov 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2031250423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250423.